Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.

@article{RussellJones2015InsulinDR,
  title={Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.},
  author={David Russell-Jones and M A Gall and Marcus Niemeyer and Michaela Diamant and Stefano Del Prato},
  journal={Nutrition, metabolism, and cardiovascular diseases : NMCD},
  year={2015},
  volume={25 10},
  pages={898-905}
}
BACKGROUND AND AIMS Basal insulin analogues have a reduced risk of hypoglycaemia compared with NPH insulin, but hypoglycaemia still remains a major impediment to achieving recommended fasting plasma glucose (FPG) targets in patients with diabetes. Insulin degludec (IDeg) is a new basal insulin that forms soluble multihexamers after subcutaneous injection resulting in an ultra-long duration of action and stable glucose-lowering effect. The aim of this analysis was to compare the effect of IDeg… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Achieving fasting plasma glucose target without nocturnal hypoglycaemia: a pooled analysis of studies in type 2 diabetes comparing insulin degludec vs insulin glargine (Poster S1051)

B Zinman, J Vora, M Niemeyer, MA Gall, C. Mathieu
Last accessed • 2014
View 2 Excerpts

Similar Papers

Loading similar papers…